Epclusa (velpatasvir/sofosbuvir) for Hepatitis C Medically reviewed by Dena Westphalen, PharmD on December 20, 2018 — Written by Lindsay Slowiczek, PharmD Reprinted with permission of Healthline. About Generic Side effects Cost Epclusa and alcohol Dosage Adherence Uses Alternatives Epclusa vs. Harvoni Epclusa vs. Mavyret Epclusa vs. Vosevi Interactions Epclusa and ribavirin How to take […]
Tag Archives: hepatitis c
16
May
May
Released in 2016, Epclusa has the remarkable ability to cure 96% of Hepatitis C sufferers regardless of genotype. It was an exciting new drug from Gilead Sciences, the innovator of the breakthrough medication Harvoni. Unfortunately, similar to Harvoni, which was released two years prior, the excitement was short lived due to the price tag. While […]
06
Feb
Feb
Jules Levin at NATAP has provided this awesome summary of the presentations from the combined AASLD/EASL HCV elimination conference. The first one starts with the elephant in the room, namely the prices… The Cost of HCV Elimination – AASLD-EASL HCV Special Conference Miami 2/1/19 – (02/04/19) Is There a Need to Re-Focus our Efforts for […]
27
Oct
Oct
So you’ve made it! SVR12 and you are cured of Hep C. Maybe you battled your insurance company for access to the medications. Maybe you sourced generic medications yourself. For most patients at this point that’s it. It’s over. You’re cured and Hepatitis C can drift quietly into the past, but there is one group […]
Blogs
Great News For Australian Patients – MAVIRET® (glecaprevir/pibrentasvir) PBS listed on 1 August 2018
26
Jul
Jul
News Flash MAVIRET® (glecaprevir/pibrentasvir) was listed on the PBS in Australia today. AbbVie is pleased to announce that MAVIRET is to be listed on the PBS on 1 August 2018 for the treatment of chronic hepatitis C virus (HCV) infection in adults. MAVIRET is a new 8 week pangenotypic treatment for treatment-naïve non-cirrhotic HCV adult […]
03
Nov
Nov
We have the power to FixHepC, but the real question is… Do we have the willpower? This was how Dr James Freeman ended his presentation at the World Hepatitis Summit in Brazil. You can watch the full presentation on YouTube. In essence, if we applied the same effort to HCV as we do to HIV […]
01
Nov
Nov
Hepatitis C is a disease that can make you feel old before your time. While there is no doubt that treatment with the new generation of direct acting antivirals like Harvoni is by far the best option this is not available to everyone, either because they don’t qualify under their insurance, don’t have insurance, or […]
10
Aug
Aug
“To our knowledge, this is the first large-scale study to demonstrate the effect of newer DAA regimens upon survival. Treatment with 2 commonly used DAA regimens, PrOD and LDV/SOF, was associated with significant improvements in survival within the first 18 months of treatment, compared with demographically and clinically similar untreated HCV-infected controls. Treatment with either […]
In the world of Hepatitis C, the chances of getting the medical insurance to cover the high costs of your drugs comes down to a fibrosis score of an individual patient. In the US for example, Medicaid providers will in many cases cover the $94,500 Hepatitis C drug Harvoni costs only to the sickest patients, […]
08
Dec
Dec
HYDERABAD, DEC 8: Generic pharmaceutical company Hetero today announced that it has received the approval for the fixed-dose combination Ledipasvir-Sofosbuvir (90mg/400mg) from the Drug Controller General of India (DCGI). The drug, Ledisof, is a generic version of Gilead Sciences’ brand Harvoni which is approved by the US FDA. The Hyderabad based Hetero had signed a […]
- 1
- 2